Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A National Platform and Scoring System Allocates CAR-T Treatment Slots for Multiple Myeloma to Patients with High Likelihood of Complete Remission

Christoph Driessen, Katharina Baur, Dominik Heim, Sabine Gerull, Christoph Renner, Anne Cairoli, Thomas Pabst, Joerg Halter, Michael Gregor, Nicole Graf, Nino Fejzibegovic, Nathan Wolfensberger, Federico Simonetta, Martin Fehr, Esteban Ciliberti, Rouven Müller, Barbara Jeker

Blood (2023) 142 (Supplement 1): 4701.

https://doi.org/10.1182/blood-2023-182628

Published: 2023

Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Blood (2021) 138 (Supplement 1): 1303.

https://doi.org/10.1182/blood-2021-148129

Published: 2021

Journal Articles

Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans

Blood (2019) 134 (Supplement_1): 234.

https://doi.org/10.1182/blood-2019-129916

Published: 2019

Journal Articles

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Adrian F Ochsenbein, MD, Carsten Riether, PhD, Ulrike Bacher, Rouven Müller, MD, Sabine Höpner, PhD, Yara Banz, Magdalena Hinterbrandner, Msc, Mario Bargetzi, MD, Markus G. Manz, MD, Luc Van Rompaey, PhD, Mahan Moshir, MSc, Tim Delahaye, MSc, Domenica Gandini, MD PhD, Ellen Erzeel, Anna Hultberg, PhD, Samson Fung, MD, Hans De Haard, PhD, Nicolas Leupin, MD, Thomas Pabst, MD PhD

Blood (2018) 132 (Supplement 1): 2680.

https://doi.org/10.1182/blood-2018-99-118302

Published: 2018

Journal Articles

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Nicolas Mach, Axel Rüfer, Ulrich Mey, Panagiotis Samaras, Karin Ribi, Lenka Besse, Andrej Besse, Catherine Berset, Stephanie Rondeau, Hanne Hawle, Felicitas Hitz, Thomas Pabst, Thilo Zander

Blood (2018) 132 (19): 2097–2100.

https://doi.org/10.1182/blood-2018-05-851170

Published: 2018

Includes: Supplemental data

Journal Articles

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Guido Ghilardi, MD, Thomas Pabst, MD, Barbara Jeker, MD, Rouven Müller, MD, Anne Cairoli, MD, Antonia Mueller, MD, Mario Bargetzi, MD, Felicitas Hitz, MD, Helen Baldomero, Dominik Heim, MD, Davide Rossi, MD PhD, Michele Ghielmini, MD, Erika Lerch, MD, Urs Schanz, MD, Jakob R. Passweg, MDMS, Georg Stussi, MD, Martina Kleber, MD, Bernhard Gerber

Blood (2017) 130 (Supplement 1): 3297.

https://doi.org/10.1182/blood.V130.Suppl_1.3297.3297

Published: 2017

Journal Articles

Inv(16) AML Engrafts Human Cytokine Knock-in Mice

Philipp J Rauch, MD, Jana M Ellegast, MD, Larisa V Kovtonyuk, PhD, Ulrich Wagner, PhD, Rouven Müller, MD, Yasuyuki Saito, MD PhD, Nicole Wildner-Verhey van Wijk, PhD, Christine Fritz, Anahita Rafiei, PhD, Veronika Lysenko, Ewa Dudkiewicz, Davide Soldini, MD PhD, Jeroen S Goede, MD, Richard Flavell, PhD, Markus G Manz, MD

Blood (2016) 128 (22): 1078.

https://doi.org/10.1182/blood.V128.22.1078.1078

Published: 2016

Journal Articles

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Christoph Driessen, MD PhD, Rouven Müller, MD, Urban Novak, MD, Nathan Cantoni, MD, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, MD, Catherine Berset, Stephanie Rondeau, Hanne Hawle, MD, Felicitas Hitz, MD, Thomas Pabst, MD PhD, Thilo Zander, MD

Blood (2016) 128 (22): 487.

https://doi.org/10.1182/blood.V128.22.487.487

Published: 2016

Journal Articles

inv(16) and NPM1 mut AMLs engraft human cytokine knock-in mice

Jana M. Ellegast, Philipp J. Rauch, Larisa V. Kovtonyuk, Rouven Müller, Ulrich Wagner, Yasuyuki Saito, Nicole Wildner-Verhey van Wijk, Christine Fritz, Anahita Rafiei, Veronika Lysenko, Ewa Dudkiewicz, Alexandre P. Theocharides, Davide Soldini, Jeroen S. Goede, Richard A. Flavell, Markus G. Manz

Blood (2016) 128 (17): 2130–2134.

https://doi.org/10.1182/blood-2015-12-689356

Published: 2016

Includes: Supplemental data

Journal Articles

Adult Donor-Derived Human CD34 + Cell Engraftment and Hemato-Lymphoid System Development in 3rd Generation Humanized Mice

Yasuyuki Saito, MD PhD, Jana M. Ellegast, MD, Rouven Müller, MD, Richard A. Flavell, PhD, Markus G. Manz, MD

Blood (2014) 124 (21): 4378.

https://doi.org/10.1182/blood.V124.21.4378.4378

Published: 2014

Journal Articles

Next Generation Humanized Mice Support Engraftment of Myelofibrosis CD34+ Cells

Alexandre P.A. Theocharides, MD, Rouven Müller, MD, Yasuyuki Saito, MD PhD, Richard A. Flavell, PhD, Markus G. Manz, MD

Blood (2014) 124 (21): 1880.

https://doi.org/10.1182/blood.V124.21.1880.1880

Published: 2014

Journal Articles

Engraftment Of Human Polycythemia Vera CD34+ Cells In hSIRPα-Transgenic-Human-TPO-Expressing RAG2 -/- , IL2Rγ -/- Immunodeficient Mice

Rouven Müller, MD, Alexandre Theocharides, MD, Renate Looser, Radek C. Skoda, M.D., Richard A. Flavell, PhD, Markus G. Manz, MD

Blood (2013) 122 (21): 2844.

https://doi.org/10.1182/blood.V122.21.2844.2844

Published: 2013

Journal Articles

Contribution of Human T Cell Subpopulations to Xenogeneic Graft-Versus-Host Disease In RAG2 −/− g c −/− Mice

Chiara Borsotti, MSc, Rouven Muller, MD, Masao Yamasaki, PhD, Markus G. Manz, MD

Blood (2010) 116 (21): 2542.

https://doi.org/10.1182/blood.V116.21.2542.2542

Published: 2010

NARROW

A National Platform and Scoring System Allocates CAR-T Treatment Slots for Multiple Myeloma to Patients with High Likelihood of Complete Remission

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Inv(16) AML Engrafts Human Cytokine Knock-in Mice

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

inv(16) and NPM1 mut AMLs engraft human cytokine knock-in mice

Adult Donor-Derived Human CD34 + Cell Engraftment and Hemato-Lymphoid System Development in 3rd Generation Humanized Mice

Next Generation Humanized Mice Support Engraftment of Myelofibrosis CD34+ Cells

Engraftment Of Human Polycythemia Vera CD34+ Cells In hSIRPα-Transgenic-Human-TPO-Expressing RAG2 -/- , IL2Rγ -/- Immunodeficient Mice

Contribution of Human T Cell Subpopulations to Xenogeneic Graft-Versus-Host Disease In RAG2 −/− g c −/− Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only